Derma Sciences (DSCI) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Piper Jaffray Cuts Price Target on Derma Sciences (DSCI) Following Mixed 3Q Results
November 10, 2015 9:33 AM ESTPiper Jaffray reiterated a Neutral rating on Derma Sciences (NASDAQ: DSCI), and cut the price target to $6.00 (from $7.00), following the company's 3Q earnings report. Derma Sciences reported net earnings per share of ($0.35), beating consensus of ($0.43), on revenues of $22M (vs. Street's 22.31M).
Analyst David Amsellem... More
